CAJ | 학술논문

目的探讨HBV相关性肝细胞癌患者血清微RNA-574-3p的表达水平及其辅助诊断的价值.方法纳入90例HBV相关性肝细胞癌患者、40例HBV相关性肝硬化患者和50名健康对照者.检测所有受试者血清标本中微RNA-574-3p的表达水平、AFP和α-L-岩藻糖苷酶(AFU)的含量.比较不同组间血清微RNA-574-3p水平的差异,分析肝细胞癌患者血清微RNA-574-3p水平与其临床病理特征之间的关系,均采用t检验.采用Spearman相关性分析肝细胞癌患者血清微RNA-574-3p水平与AFP,AFU的关系,应用ROC曲线及AUC(95％CI)评估它们作为诊断指标的诊断效能.结果肝细胞癌组、肝硬化组与健康对照组血清微RNA-574-3p的相对表达量分别为2.152(1.654,3.061)、1.292(0.984,1.666)和1.018(0.750,1.726).肝细胞癌患者血清微RNA-574-3p表达量高于肝硬化患者和健康对照者,差异均有统计学意义(t=2.726,2.845;P均＜0.01).肝细胞癌患者血清微RNA-574-3p相对表达量在不同的分化程度(t=2.262,P=0.039)、肿瘤分期(t=2.354,P=0.025)和HBVDNA含量(t=2.771,P＜0.01)间差异均有统计学意义.肝细胞癌患者血清微RNA-574-3p相对表达量与AFP,AFU之间无相关性(r2=0.076,P=0.505;r2=0.082,P=0.422).肝细胞癌组与肝硬化组比较,血清微RNA-574-3p的AUC为0.823,95％CI为0.750～0.897;肝细胞癌组与健康对照组比较,血清微RNA-574-3p的AUC为0.840,95％CI为0.769～0.910.结论肝细胞癌患者血清微RNA-574-3p含量高于肝硬化患者和健康对照者.血清微RNA-574-3p可能是一个重要的诊断肝细胞癌的生物学指标.
목적 탐토HBV상관성간세포암환자혈청미RNA-574-3p적표체수평급기보조진단적개치.방법 납입90례HBV상관성간세포암환자、40례HBV상관성간경화환자화50명건강대조자.검측소유수시자혈청표본중미RNA-574-3p적표체수평、AFP화α-L-암조당감매(AFU)적함량.비교불동조간혈청미RNA-574-3p수평적차이,분석간세포암환자혈청미RNA-574-3p수평여기림상병리특정지간적관계,균채용t검험.채용Spearman상관성분석간세포암환자혈청미RNA-574-3p수평여AFP,AFU적관계,응용ROC곡선급AUC(95％CI)평고타문작위진단지표적진단효능.결과 간세포암조、간경화조여건강대조조혈청미RNA-574-3p적상대표체량분별위2.152(1.654,3.061)、1.292(0.984,1.666)화1.018(0.750,1.726).간세포암환자혈청미RNA-574-3p표체량고우간경화환자화건강대조자,차이균유통계학의의(t=2.726,2.845;P균＜0.01).간세포암환자혈청미RNA-574-3p상대표체량재불동적분화정도(t=2.262,P=0.039)、종류분기(t=2.354,P=0.025)화HBVDNA함량(t=2.771,P＜0.01)간차이균유통계학의의.간세포암환자혈청미RNA-574-3p상대표체량여AFP,AFU지간무상관성(r2=0.076,P=0.505;r2=0.082,P=0.422).간세포암조여간경화조비교,혈청미RNA-574-3p적AUC위0.823,95％CI위0.750～0.897;간세포암조여건강대조조비교,혈청미RNA-574-3p적AUC위0.840,95％CI위0.769～0.910.결론 간세포암환자혈청미RNA-574-3p함량고우간경화환자화건강대조자.혈청미RNA-574-3p가능시일개중요적진단간세포암적생물학지표.
Objective To explore the expression and diagnostic value of serum microRNA-574-3p (miR-574-3p) in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).Methods A total of 90 patients with HBV-related HCC,40 patients with HBV-related liver cirrhosis (LC) and 50 healthy controls were recruited.The expression levels of serum miR-574-3p,α-fetoprotein (AFP) and α-Lfucosidase (AFU) of all subjects were determined.The difference of serum miR-574-3p level between groups was compared.The relation between serum miR-574-3p level of HCC patients and its clinical pathological characteristics was analyzed.The t-test was performed.The relationship between serum miR-574-3p level of HCC patients and AFP,AFU was analyzed by Spearman correlation analysis.The diagnostic efficacy of them as diagnostic markers was evaluated by receiver operating characteristic curves (ROC) and the area under the curve (AUC)(95％ CI (confidence interval)).Results The relative quantity expression of serum miR-574-3p of HCC group,LC group and healthy group was 2.152(1.654,3.061),1.292 (0.984,1.666) and 1.018 (0.750,1.726),respectively.The expression level of serum miR-574-3p of HCC group was significantly higher than those of LC group and healthy control group,and the differences were statistically significant (t=2.726 and 2.845,both P＜0.01).The expression level of serum miR-574-3p of HCC patients was significantly different in tumors with different degree of differentiation (t=2.262,P=0.039),different stage (t=2.354,P=0.025) and different HBV DNA concentrations (t=2.771,P＜0.01).There was no correlation between serum miR-574-3p level and AFP (r2 =0.076,P=0.505),AFU (r2 =0.082,P=0.422) in HCC patients.When compared HCC group with LC group,AUC of serum miR-574-3p of was 0.823 and 95％ CI was 0.750 to 0.897.When compared HCC group with healthy control group,AUC of serum miR-574-3p was 0.840 and 95％CI was 0.769 to 0.910.Conclusions The expression level of serum miR-574-3p of HCC patients is significantly higher than those of LC patients and healthy controls.Serum miR-574-3p may be an important biomarker in the diagnosis of HCC.